JP2013505265A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505265A5
JP2013505265A5 JP2012529958A JP2012529958A JP2013505265A5 JP 2013505265 A5 JP2013505265 A5 JP 2013505265A5 JP 2012529958 A JP2012529958 A JP 2012529958A JP 2012529958 A JP2012529958 A JP 2012529958A JP 2013505265 A5 JP2013505265 A5 JP 2013505265A5
Authority
JP
Japan
Prior art keywords
compound
cdcl
nmr
mhz
procedure similar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012529958A
Other languages
English (en)
Other versions
JP2013505265A (ja
JP5795766B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/049471 external-priority patent/WO2011035231A1/en
Publication of JP2013505265A publication Critical patent/JP2013505265A/ja
Publication of JP2013505265A5 publication Critical patent/JP2013505265A5/ja
Application granted granted Critical
Publication of JP5795766B2 publication Critical patent/JP5795766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

化合物C−6は、化合物C−1に関して例示されるものと同様の手順であるが、化合物3およびC−1aのスルホン類似体を使用して得た。
H NMR(400 MHz,CDCl)δ 7.93(s,1 H),7.89(s,1 H),7.35−7.01(m,5 H),6.93(d,J=2.8 Hz,,1 H),6.58(d,J=2.8 Hz,1H),5.79(bs,2 H),4.30(s,6 H),4.11(d,J=7.0 Hz,6H),3.10−2.84(m,3 H),2.75(s,3 H),2.54(s,6 H),1.31−1.15(m,6 H).
31P NMR(162 MHz,CDCl)δ 3.39,3.33.
19F NMR(376 MHz,CDCl)δ−152.40
LC MS m/z 655.24[M+H+]。

化合物6
Figure 2013505265

JP2012529958A 2009-09-21 2010-09-20 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体 Active JP5795766B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24429709P 2009-09-21 2009-09-21
US61/244,297 2009-09-21
PCT/US2010/049471 WO2011035231A1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015098728A Division JP6033362B2 (ja) 2009-09-21 2015-05-14 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体

Publications (3)

Publication Number Publication Date
JP2013505265A JP2013505265A (ja) 2013-02-14
JP2013505265A5 true JP2013505265A5 (ja) 2014-12-25
JP5795766B2 JP5795766B2 (ja) 2015-10-14

Family

ID=43031517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012529958A Active JP5795766B2 (ja) 2009-09-21 2010-09-20 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
JP2015098728A Active JP6033362B2 (ja) 2009-09-21 2015-05-14 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
JP2016207475A Withdrawn JP2017075146A (ja) 2009-09-21 2016-10-24 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015098728A Active JP6033362B2 (ja) 2009-09-21 2015-05-14 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体
JP2016207475A Withdrawn JP2017075146A (ja) 2009-09-21 2016-10-24 抗ウイルス治療のための2′−フルオロ置換カルバ−ヌクレオシド類似体

Country Status (32)

Country Link
EP (2) EP3150608B1 (ja)
JP (3) JP5795766B2 (ja)
KR (2) KR20180006499A (ja)
CN (1) CN102596958A (ja)
AP (1) AP2012006189A0 (ja)
AU (4) AU2010295373B2 (ja)
BR (3) BR112012006261B1 (ja)
CA (1) CA2773772C (ja)
CL (1) CL2012000707A1 (ja)
CR (2) CR20190103A (ja)
CY (1) CY1118605T1 (ja)
DK (1) DK2480552T3 (ja)
EA (1) EA201200525A1 (ja)
EC (1) ECSP12011817A (ja)
ES (2) ES2730805T3 (ja)
HR (1) HRP20170197T1 (ja)
HU (1) HUE032252T2 (ja)
IL (2) IL218599A (ja)
LT (1) LT2480552T (ja)
ME (1) ME02656B (ja)
MX (1) MX352646B (ja)
NZ (1) NZ599402A (ja)
PE (3) PE20120995A1 (ja)
PL (1) PL2480552T3 (ja)
PT (1) PT2480552T (ja)
RS (1) RS55699B1 (ja)
SG (1) SG179194A1 (ja)
SI (1) SI2480552T1 (ja)
SM (1) SMT201700091B (ja)
UA (1) UA110466C2 (ja)
WO (1) WO2011035231A1 (ja)
ZA (1) ZA201202175B (ja)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588400A (en) 2008-04-23 2012-08-31 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
JP5767643B2 (ja) * 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド 1’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
RS55699B1 (sr) * 2009-09-21 2017-07-31 Gilead Sciences 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) * 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2551944T3 (es) * 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
KR101879887B1 (ko) * 2010-09-20 2018-07-18 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체
UA114075C2 (xx) 2010-11-19 2017-04-25 БАГАТОШАРОВА ТАБЛЕТКА, ЩО МІСТИТЬ РИЛПІВІРИН HCl, ЕМТРИЦИТАБІН І ТЕНОФОВІРУ ДИЗОПРОКСИЛФУМАРАТ
CA2822037A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9481704B2 (en) 2012-03-13 2016-11-01 Gilead Sciences, Inc. 2′-substituted carba-nucleoside analogs for antiviral treatment
EP2909209B1 (en) * 2012-10-17 2022-08-03 Merck Sharp & Dohme LLC 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US9457039B2 (en) 2012-10-17 2016-10-04 Merck Sharp & Dohme Corp. 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
CA2891125A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
EP3010512B1 (en) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015095419A1 (en) * 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 2’-氯胺基嘧啶酮及嘧啶二酮核苷類
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
WO2016160646A1 (en) 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
CN104945437B (zh) * 2015-05-19 2017-03-01 广州诺威生物技术有限公司 一种嘧啶类新化合物
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
TWI740910B (zh) * 2016-03-09 2021-10-01 美商艾洛斯生物製藥公司 非環抗病毒劑
SG10202009423QA (en) 2016-03-28 2020-11-27 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
MA45925A (fr) * 2016-08-12 2019-06-19 Janssen Biopharma Inc Nucléosides et nucléotides substitués et leurs analogues
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
ES2961460T3 (es) 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
MX2020005392A (es) 2017-12-07 2020-12-07 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
CA3129178A1 (en) * 2019-02-07 2020-08-13 Beigene, Ltd. Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
CN114127082A (zh) 2019-05-09 2022-03-01 阿里戈斯治疗公司 作为sting调节剂的经修饰的环状二核苷化合物
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス化合物
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
TW202315607A (zh) 2020-02-18 2023-04-16 美商基利科學股份有限公司 抗病毒化合物
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノヌクレオシドを調製する方法
AU2021251689A1 (en) 2020-04-06 2022-11-17 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
WO2021262826A2 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TW202228722A (zh) 2020-08-27 2022-08-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
WO2022219636A1 (en) * 2021-04-14 2022-10-20 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds, and uses thereof
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
JP2024518530A (ja) * 2021-05-14 2024-05-01 ビーエム ファーマ コンサルティング ピーティーワイ リミテッド ウイルス感染の予防及び治療のための二環式複素環化合物
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
WO2001060315A2 (en) 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
CZ20032005A3 (en) * 2001-01-22 2004-04-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′-支链核苷和黄病毒突变
ES2769377T3 (es) 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷
EP1804812A4 (en) * 2004-10-21 2009-09-02 Merck & Co Inc FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2673649A1 (en) 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
DK2155758T3 (da) 2007-05-10 2012-11-05 Biocryst Pharm Inc Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
NZ588400A (en) 2008-04-23 2012-08-31 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
RS55699B1 (sr) * 2009-09-21 2017-07-31 Gilead Sciences 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje
JP5767643B2 (ja) * 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド 1’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体

Similar Documents

Publication Publication Date Title
JP2013505265A5 (ja)
IL246265B (en) A method for the production of intermediates for the preparation of 5-fluoro-h1-pyrazolopyridines and such compounds
JP2012527477A5 (ja)
PL2289864T3 (pl) Proces otrzymywania związków fluorowych
EP2480320A4 (en) METHOD FOR ENHANCING THE SELECTIVITY OF POLYBENZOXAZOLE MEMBRANES
EP2274266A4 (en) PROCESS FOR THE PREPARATION OF PROSTAGLANDIN ANALOGS AND THEIR INTERMEDIATES
EP3392368B8 (en) Use of beta-fesi2 phase material as a solar-thermal conversion member and method of producing it
JP2013532130A5 (ja)
EP2310347A4 (en) PROCESS FOR THE PREPARATION OF PERFLUORATED CIS-ALKEN
IL220936A0 (en) Process for the synthesis of lacosamide
EP3444238A3 (en) Process for preparing difluoromethylene compounds
JP2011519871A5 (ja)
JP2010209099A5 (ja)
HRP20181437T1 (hr) Postupak proizvodnje (3s,3s') 4,4' disulfanedilbis (3-aminobutan-1-sulfonske kiseline)
JP2012094862A5 (ja)
IL219913A0 (en) New process for the preparation of tapentadol and intermediates thereof
ITMI20072262A1 (it) Procedimento per la preparazione di acido (s)(+)-3-(amminometil)-5-metilesanoico
IL223066A0 (en) New process for the synthesis of tapentadol and intermediates thereof
BR112012017828A2 (pt) ''método para a produção de um produto químico por fermentação contínua''
ITMI20071261A1 (it) Procedimento per la preparazione di cinacalcet
ITBS20100012A1 (it) Procedimento per la preparazione di fluazinam
EP2586763A4 (en) PROCESS FOR PREPARING 1,1-DICHLOR-2,2,3,3,3-PENTA-FLUORO-PROPANE
HK1186172A1 (zh) 製備 -氟- -羥基亞甲基- -氧代丁酸酯的烯醇鹽方法
JP2014526571A5 (ja)
IL211266A0 (en) Improved process for the addition of thiolates to alfa, beta-unsaturated carbonyl or sulfonyl compounds